Pathological predictive factors are the most important markers when selecting early breast cancer adjuvant therapy. In randomized clinical trials the variability in pathology report after central pathology review is noteworthy. We evaluated the discordance rate (DR) and inter-rater agreement between local and central histopathological report and the clinical implication on treatment decision.

Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment

Bria, Emilio;Carbognin, Luisa;CALIOLO, Chiara;
2016-01-01

Abstract

Pathological predictive factors are the most important markers when selecting early breast cancer adjuvant therapy. In randomized clinical trials the variability in pathology report after central pathology review is noteworthy. We evaluated the discordance rate (DR) and inter-rater agreement between local and central histopathological report and the clinical implication on treatment decision.
2016
Early breast cancer; Pathology report
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/953218
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 32
social impact